October 27, 2018 / 2:13 PM / 18 days ago

BRIEF-Novartis touts data from experimental eye drug, says beats rival

Oct 27 (Reuters) - Novartis AG:

* NOVARTIS SAYS TWO-YEAR DATA FOR BROLUCIZUMAB (RTH258) REAFFIRM SUPERIORITY VERSUS AFLIBERCEPT IN REDUCING RETINAL FLUID IN PATIENTS WITH NAMD

* NOVARTIS PLANS TO FILE FOR APPROVAL IN DECEMBER Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below